---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-044241"
form_type: "8-K"
ticker: null
cik: "0001741830"
company_name: "Kronos Bio, Inc."
filed_at: "2023-09-18T23:59:59+00:00"
generated_at: "2026-06-10T15:01:02.607776+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kronos Bio names Sandra Gardiner interim CFO starting Sept 15, 2023

## Summary
- Appointed interim CFO, principal financial and accounting officer effective at close of business Sept 15, 2023.
- Compensation: $650 per hour paid to FLG Partners under consulting agreement; no direct employment with Kronos.
- Gardiner previously served as CFO of Pulse Biosciences (PLSE) from Nov 2019 to Dec 2022 and Cutera (CUTR) from July 2017 to Nov 2019.
- She currently serves as acting CFO of Anebulo Pharmaceuticals (ANEB) under an agreement ending Sept 28, 2023.
- Agreement with FLG is terminable by either party on 30 days' notice; includes standard indemnification provisions.

## SEC filing metadata
- accession: 0001140361-23-044241
- form_type: 8-K
- cik: 0001741830
- company_name: Kronos Bio, Inc.
- filed_at: 2023-09-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1741830/000114036123044241/0001140361-23-044241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1741830/000114036123044241/ef20010826_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-044241
- JSON: https://secwatch.observer/filing/0001140361-23-044241.json
- Plain text: https://secwatch.observer/filing/0001140361-23-044241.txt

## Key facts
- Executive change
  Sandra A. Gardiner was appointed as interim Chief Financial Officer at Kronos Bio, Inc..
  - Action: appointed
  - Role: interim Chief Financial Officer
  source text: On September 14, 2023, the Board of Directors of Kronos Bio, Inc. (the “Company”) appointed Sandra A. Gardiner as the Company’s interim Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective at the close of business on September 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1741830/000114036123044241/0001140361-23-044241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.